Analyst Price Targets — ELOX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 20, 2026 10:05 am | Dev Prasad | Loop Capital Markets | $38.00 | $18.16 | StreetInsider | Lucid Capital Markets Starts Eloxx Pharma (ELOX) at Buy |
| July 20, 2026 12:43 am | — | Guggenheim | $43.00 | $12.00 | TheFly | Eloxx Pharmaceuticals initiated with a Buy at Guggenheim |
Latest News for ELOX
Completed underwritten public offering with gross proceeds of $66.0 million and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheet Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome expected to initiate in the third quarter of 2026 European Commission granted orphan designation for exaluren in ADPKD Cash and cash equivalents of $62.0 million as of…
ARLINGTON, Mass., June 8, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) ("Eloxx" and the "Company"), a clinical-stage biopharmaceutical company developing novel, small molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations to enable the production of full-length proteins, today announced the pricing of a public…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ELOX.
U.S. House Trading
No House trades found for ELOX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.